Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib

BACKGROUND: Sunitinib and pazopanib are among the most prescribed targeted therapies for the systemic management of advanced renal cell carcinoma (RCC), but published cost comparisons between the 2 agents are few and limited by methodological and population differences. Also, sunitinib is administer...

Descripción completa

Detalles Bibliográficos
Autores principales: MacLean, Elizabeth, Mardekian, Jack, Cisar, Laura A., Hoang, Caroline J., Harnett, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397739/
https://www.ncbi.nlm.nih.gov/pubmed/27459661
http://dx.doi.org/10.18553/jmcp.2016.22.8.979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397739/
https://www.ncbi.nlm.nih.gov/pubmed/27459661
http://dx.doi.org/10.18553/jmcp.2016.22.8.979

Ejemplares similares